GHM
GRAHAM CORP
Next earnings Aug 3, 2026 · consensus $0.37 EPS, $66.3M rev
Last earnings -11.0% on 2026-06-08
$121.66
▼ -0.95%$121.66▲ +151.36%
over 1Y
L $46.97EODHDH $122.83
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-1.0%
1W+12.7%
1M+21.7%
3M+55.7%
YTD+83.3%
1Y+151.4%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 9 analysts
Buy
Revenue grew 16.9% YoY; but very expensive (P/E 109.2).
Revenue (FY2026) $245M · FY2026
The read
Middling fundamentals and a rich price (~79% above fair value) leave little margin of safety — a wait-and-see.
GRAHAM CORP shows $245M in FY2026 revenue (+16.9% YoY), a 5.1% net margin, and 8.9% ROE.
Financials · annual, by fiscal year
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | $123M | $157M | $186M | $210M | $245M |
| Gross profit | $9.13M | $25.4M | $40.6M | $52.9M | $57.8M |
| Operating income | -$11.3M | $1.25M | $6.92M | $15.2M | $15.0M |
| Net income | -$8.77M | $367K | $4.56M | $12.2M | $12.5M |
| Diluted EPS | -$0.83 | $0.03 | $0.42 | $1.11 | $1.12 |
| Net margin | -7.1% | 0.2% | 2.5% | 5.8% | 5.1% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$1.43B
EV / EBITDA62.5
EV / Sales5.8
EV / FCF—
P / FCF—
PEG (trailing)49.20
Earnings yield0.9%
FCF yield-0.0%
Quality & risk
ROIC (est.)7.7%
Free cash flow-$121K
Total debt$13.0M
Net cash-$6.42M
Altman Z-Score6.03 safe
Piotroski F-Score3/9
Capital returns
Buyback yield0.1%
Dividend yield (est.)0.0%
Shareholder yield0.1%
Shares Δ YoY+6.8%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
- 8-K Reg FD disclosure2026-06-18
- 8-K Officer / director change2026-06-17
- 8-K Earnings results2026-06-08
- 10-K Annual report2026-06-08
- 8-K Officer / director change2026-06-05
- S-3 Shelf registration (potential raise)2026-04-30
- 8-K Material agreement2026-04-15
- 8-K Officer / director change2026-03-30
- 10-Q Quarterly report2026-02-06
Recent filings
all on EDGAR ↗144Filing2026-06-23open ↗11-KPeriod ending 2026-03-312026-06-18open ↗8-KPeriod ending 2026-06-182026-06-18open ↗8-KPeriod ending 2026-06-152026-06-17open ↗4Period ending 2026-06-082026-06-10open ↗4Period ending 2026-06-082026-06-10open ↗4Period ending 2026-06-082026-06-10open ↗4Period ending 2026-06-042026-06-08open ↗4Period ending 2026-06-042026-06-08open ↗4Period ending 2026-06-042026-06-08open ↗10-KPeriod ending 2026-03-312026-06-08open ↗8-KPeriod ending 2026-06-082026-06-08open ↗
Frequently asked
- Is GRAHAM CORP (GHM) a buy?
- GHM currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Revenue grew 16.9% YoY; but very expensive (P/E 109.2).
- What is GHM's fair value?
- A Modified-Graham model based on GHM's SEC fundamentals estimates a fair value of about $25.54. It is an estimate from reported earnings, not a price target.
- Is GHM overvalued or undervalued?
- Against a Modified-Graham fair-value estimate, GHM currently appears overvalued relative to its SEC-grounded earnings power.
- What is GRAHAM CORP's quality score?
- GHM scores 60.843137254901954/100 (grade C+) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0000716314, latest 10-K filed 2026-06-08) · EODHD · as of 6/25/2026, 6:08:32 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.